Collaboration with Janssen aims to fast-track the launch and enhance accessibility to YESINTEK for patients in need.

YESINTEK works by targeting specific proteins that contribute to inflammation, offering a new treatment option for patients ...

Topline results were announced from a phase 3 trial evaluating icotrokinra in patients with moderate to severe plaque psoriasis (PsO).

Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical ...

Johnson & Johnson (J&J) and Protagonist Therapeutics have announced positive top-line results from a late-stage study of ...

Johnson & Johnson (NYSE: JNJ) has announced encouraging results from its Phase 3 investigational study of icotrokinra ...

Phase 3 psoriasis trial results highlight the efficacy and safety of icotrokinra, an oral IL-23 therapy showing promise for ...

Icotrokinra is an investigational oral peptide that blocks interleukin (IL)-23 receptor, which plays a significant role in ...

This week Novartis NVS upgraded its mid-term sales growth guidance. The European Commission approved Pfizer’ s PFE hemophilia ...

The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at ...

Results for icotrokinra (JNJ-2113) have shown the drug’s potential to offer significant relief for patients suffering from moderate-to-severe plaque psorias ...

Icotrokinra is licensed to Johnson & Johnson and is currently in Phase 3 development for psoriasis and is nearing completion of Phase 2b development ... which underpins the inflammatory response in ...